Financial Performance - Bruker's Q1 2025 revenues increased by $79.7 million, representing an 11% growth compared to Q1 2024[6] - The company's constant-exchange rate (CER) growth was +12.5%[6] - Organic revenue change increased by +2.9%, with Bruker Scientific Instruments (BSI) up +5.1% and Bruker Energy & Supercon Technologies (BEST) down -17.7%[6] - Acquisitions contributed +9.6% to revenue growth, while foreign exchange (FX) had a -1.5% headwind[6] - Non-GAAP EPS decreased by -11.3% to $0.47, compared to $0.53 in Q1 2024[6] Segment Performance - Bruker BIOSPIN Group experienced mid-teens % CER revenue growth, driven by preclinical imaging and lab automation[12] - Bruker CALID Group saw mid-20s % CER revenue growth, with strong performance in Life Science Mass Spectrometry and Microbiology & Infection Diagnostics[12] - Bruker NANO Group's CER revenue increased by high single digits %, aided by NanoString acquisition[18] - Bruker Energy & Supercon Technologies (BEST) segment experienced a high teens % decline in CER revenue, primarily due to softness in superconductors for clinical MRI[18] Financial Outlook - The company projects FY 2025 revenue between $3.48 billion and $3.55 billion, representing a reported revenue growth of +3.5% to +5.5%[45] - Organic revenue growth for FY 2025 is expected to be between +0% and +2%[45] - Non-GAAP EPS for FY 2025 is projected to be between $2.40 and $2.48, with a reported EPS growth of +0% to +3%[45]